PRA Health Sciences (PRAH) Stock Rating Upgraded by BidaskClub

PRA Health Sciences (NASDAQ:PRAH) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday.

A number of other research analysts have also commented on the company. Barclays assumed coverage on PRA Health Sciences in a report on Monday, December 11th. They set an “overweight” rating and a $94.00 price target for the company. Robert W. Baird set a $94.00 price target on PRA Health Sciences and gave the stock a “buy” rating in a report on Friday, December 1st. Mizuho set a $87.00 price target on PRA Health Sciences and gave the stock a “buy” rating in a report on Friday, December 1st. KeyCorp reiterated a “buy” rating and set a $93.00 price target (up from $86.00) on shares of PRA Health Sciences in a report on Monday, October 30th. Finally, SunTrust Banks reiterated a “buy” rating and set a $101.00 price target on shares of PRA Health Sciences in a report on Friday, October 27th. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $90.46.

Shares of PRA Health Sciences (NASDAQ PRAH) traded up $1.12 during mid-day trading on Thursday, hitting $90.25. The stock had a trading volume of 1,079,186 shares, compared to its average volume of 483,123. PRA Health Sciences has a one year low of $53.47 and a one year high of $90.43. The firm has a market capitalization of $5,648.14, a price-to-earnings ratio of 32.77, a PEG ratio of 1.54 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 1.38.

PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings results on Wednesday, October 25th. The medical research company reported $0.88 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.03. PRA Health Sciences had a return on equity of 21.66% and a net margin of 5.64%. The company had revenue of $494.55 million during the quarter, compared to analyst estimates of $477.89 million. During the same period in the previous year, the company earned $0.64 earnings per share. The company’s quarterly revenue was up 23.7% compared to the same quarter last year. equities analysts expect that PRA Health Sciences will post 3.2 EPS for the current fiscal year.

In other news, Director Matthew P. Young sold 5,115 shares of the business’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $79.90, for a total transaction of $408,688.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 2.10% of the company’s stock.

A number of large investors have recently made changes to their positions in PRAH. Capital Research Global Investors grew its position in PRA Health Sciences by 318.3% in the second quarter. Capital Research Global Investors now owns 2,175,340 shares of the medical research company’s stock valued at $163,172,000 after acquiring an additional 1,655,336 shares during the period. BlackRock Inc. grew its position in PRA Health Sciences by 28.2% in the second quarter. BlackRock Inc. now owns 3,662,954 shares of the medical research company’s stock valued at $274,759,000 after acquiring an additional 805,573 shares during the period. Wells Fargo & Company MN grew its position in PRA Health Sciences by 55.8% in the third quarter. Wells Fargo & Company MN now owns 1,207,069 shares of the medical research company’s stock valued at $91,943,000 after acquiring an additional 432,449 shares during the period. Hood River Capital Management LLC grew its position in PRA Health Sciences by 80.3% in the second quarter. Hood River Capital Management LLC now owns 619,924 shares of the medical research company’s stock valued at $46,500,000 after acquiring an additional 276,045 shares during the period. Finally, Stephens Investment Management Group LLC grew its position in PRA Health Sciences by 236.9% in the third quarter. Stephens Investment Management Group LLC now owns 391,672 shares of the medical research company’s stock valued at $29,834,000 after acquiring an additional 275,414 shares during the period. Hedge funds and other institutional investors own 98.49% of the company’s stock.

TRADEMARK VIOLATION WARNING: “PRA Health Sciences (PRAH) Stock Rating Upgraded by BidaskClub” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/16/pra-health-sciences-prah-stock-rating-upgraded-by-bidaskclub.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply